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Recent in vitro and animal studies have reported estrogen-like activity of chemicals used in sunscreen
preparations. We investigated whether the three sunscreens benzophenone-3 (BP-3), octyl-methoxycinnamate
(OMC), and 3-(4-methylbenzylidene) camphor (4-MBC) were absorbed and inﬂuenced endogenous reproductive
hormone levels in humans after topical application. In this 2-wk single-blinded study 32 healthy volunteers, 15
young males and 17 postmenopausal females, were assigned to daily whole-body topical application of 2 mg per
cm2 of basic cream formulation without (week 1) and with (week 2) the three sunscreens at 10% (wt/wt) of each.
Maximum plasma concentrations were 200 ng per mL BP-3, 20 ng per mL 4-MBC, and 10 ng per mL OMC for females
and 300 ng per mL BP-3, 20 ng per mL 4-MBC, and 20 ng per mL OMC for men. All three sunscreens were detectable
in urine. The reproductive hormones FSH, LH were unchanged but minor differences in testosterone levels were
observed between the 2 wk. A minor difference in serum estradiol and inhibin B levels were observed in men only.
These differences in hormone levels were not related to sunscreen exposure.
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Terrestrial solar radiation and particularly ultraviolet radia-
tion are absorbed by chemical sunscreens. The use of
sunscreens is increasing due to growing public concern
about sunburn, photoaging, skin cancer, and to protect
against photodermatoses.
A study (Schlumpf et al, 2001) recently reported an
estrogen-like activity in vitro in MCF-7 breast cancer cells
and in vivo in the immature rat uterotrophic assay of the
most frequently used sunscreens. The orally most active
compound 3-(4-methylbenzylidene) camphor (4-MBC) also
increased uterine weight following topical application. The
two other less active substances were benzophenone-3
(BP-3) and octyl-methoxycinnamate (OMC).
Our aim was to investigate whether the three compounds
BP-3, OMC, and 4-MBC applied topically could be found in
the plasma and urine and whether systemic uptake had any
acute effect on the levels of endogenous reproductive
hormones in humans.
Thirty-two healthy Caucasian volunteers: 15 males (aged
23–29, mean 26 y) and 17 postmenopausal females (aged
54–86 y, mean 65 y) were enrolled.
Postmenopausal women were selected to achieve a
stable hormone level independent of ovarian-menstrual
cycle. The subjects were only allowed to use a sunscreen-
free moisturizer supplied by us 1 wk before the study.
Physical exercise, sun bathing, intake of caffeine, nicotine,
or alcohol were not allowed during the study.
The study lasted 2 consecutive wk; a control week
followed by a treatment week. Hereby the study became
single-blinded and the subjects served as their own control.
In both weeks subjects met Monday–Friday in our Depart-
ment of Dermatology. The time point for the first cream
application and blood sampling was noted and thereafter
performed at the same time each day. Morning urine was
collected each day. Immediately after the 0 h blood sample
basic cream formulation without sunscreens was applied
by staff to the whole body every day for 4 d. The same
procedure was used in the second week except that a daily
prepared sunscreen formulation was used. We applied 2 mg
per cm2 of cream, corresponding to 40 g for an average
body area of 2.0 m2.
The basic formulation was an Essex cream (Schering-
Plough, Brussels, Belgium). The active formulation con-
sisted of Essex cream with 10% (wt/wt) of the three
sunscreens: Eusolex 4360 (BP-3) (Merck), Eusolex 6300
(4-MBC) (Merck, Darmstadt, Germany), and Escalol 557
(OMC) (International Specialty Products, Waterfield, Tad-
worth, UK).
Serum inhibin B in males was measured in antibody
enzyme immunometric assay (Oxford-bioinnovation, UK).
Abbreviations: BP-3, benzophenone-3; 4-MBC, 3-(4-methylbenzy-
lidene) camphor; OMC, octyl-methoxycinnamate
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Inhibin B was not measured in the woman as postmeno-
pausal women all have undetectable inhibin B levels.
Serum FSH, LH, and SHBG were measured by time-
resolved immunofluorometric assay (DELFIA, Wallac, Inc.,
Turku, Finland). Testosterone and estradiol were measured
by radio immunoassay (RIA) (Coat-a-Count, Diagnostic
Products, California and ImmunoDiagnostic Systems, Bol-
don, UK).
Essential Data
Systemic uptake In all plasma samples drawn before the
first application of the active formulation BP-3, 4-MBC, and
OMC were below the detection limit.
In the postmenopausal women maximum plasma levels
of approximately 200 ng per mL BP-3, 20 ng per mL
4-MBC, and 10 ng per mL OMC were reached 3–4 h after
application. In the young men maximum plasma concentra-
tions of 300 ng per mL BP-3, 20 ng per mL 4-MBC, and 20
ng per mL OMC were reached 3 h after application.
The plasma concentrations of BP-3 at 24 and 96 h after
the first application of the active formulation were not
significantly different in neither the men nor in the women,
indicating that no accumulation occurred during the treat-
ment week. The same was true for OMC in the women. In
the men the plasma concentrations of both OMC and
4-MBC were significantly higher after 96 h than after 24 h
(po0.001 and p¼ 0.03, respectively; differences were
compared by Wilcoxon’s signed rank test).
In females urine approximately 60 ng per mL BP-3 and 5
ng per mL of 4-MBC and OMC, were found. In the males
urine 140 ng per mL BP-3, 7 ng per mL 4-MBC and 8 ng per
mL of OMC were found. In men there were no significant
change in urine levels of the three sunscreen compounds
from 24 to 96 h after the first application of sunscreen.
The same was true for 4-MBC and OMC in women, but
the concentration of BP-3 in urine increased from the 24
to the 48 h samples and remained constant thereafter.
Hormone levels There were no statistically significant
differences in the levels of FSH, LH, and SHBG in neither
the women nor in the men (Figs 1 and 2) in samples
obtained at the same time points in the control week and
the treatment week. This was also the case for estradiol
in the women. A significant difference in mean (po0.01,
differences were compared by paired t test) testosterone
levels, however, was found in women between the control
week and the treatment week at 0–3 and 24 h, but not at
4 and 96 h. As this difference was evident also in the 0-h
samples when treatment with the active formulation had not
yet started and as it was not consistent this observed
difference most likely was a chance finding not related to
the sunscreen compounds. Likewise, minor but statistically
significant differences between the 2 wk in inhibin B levels in
the 0–3-h male samples and in estradiol in the 2- and 4-h
male samples (po0.05 and po0.01; differences were
compared by paired t-test) most likely reflects chance
findings. In the men a significant difference in mean
testosterone levels (po0.05) between the 2 wk was also
found in the 4-h samples, which might suggest a more
steep diurnal decrease in testosterone during the treatment
week compared with the control week. To further explore
this a statistical model, which allowed for a general shift
in hormone levels from 1 wk to the other and for different
diurnal trends during the 2 wk, was used. In this model a
significant decrease in both inhibin B and testosterone but
not in estradiol levels was observed in the men from 0 to 4 h
on day 1 in both weeks (po0.001). This is in accordance
with the known decreasing levels during daytime. The trend
in the daytime decrease in inhibin B and in testosterone,
however, was not significantly different between the 2 wk
(p¼0.086 and 0.31, respectively).
Discussion
In the present human study, we have demonstrated for the
first time that the sunscreen compounds BP-3, OMC, and
4-MBC were absorbed through the skin and excreted in
urine. The systemic presence of these three sunscreens,
however, did not seem to have any influence on the levels of
endogenous reproductive hormones in young men and
postmenopausal women.
Absorption of BP-3 and OMC into the stratum corneum
of Micro-Yucatan pigskin reaches a peak level within an
hour and OMC had a lower skin penetration than BP-3,
although this effect was depending upon formulation (Gupta
et al, 1999). Evidence for percutaneous absorption of
4-MBC through human skin has been presented in an
experimental model with very small skin areas of 12
subjects in vivo (Hagedorn-Leweke and Lippold 1995). In
our study, BP-3 also gave a higher plasma concentration
than 4-MBC and OMC, which indicates that the two latter
have the same skin penetration abilities in this formulation
as in the experimental setting.
A small sex difference in plasma concentrations might be
explained by an age difference between the groups. Body
fat increases from 33% to 45% in women with age, and
increased body fat increases the volume of distribution for
lipophilic drugs and may result in increased plasma
elimination half-lives (Cusack and Evestal, 2000).
From our experimental design, we did not intend to
estimate the amount absorbed of the three compounds. It
has been estimated, however, that over a 10-h period the
amount of BP-3 being absorbed through the skin was 1%–
2% of the topically applied amount (Hayden et al, 1997).
Thus the systemic uptake of BP-3 may be in the order of
milligrams per application.
The plasma levels of 4-MBC increased from 24 to 96 h in
both genders and the same was true for OMC in the young
men, indicating accumulation after repeated daily applica-
tions. The excretion in urine did not show a similar increase.
In women, however, BP-3 in urine increased from 24 to 48 h,
which is in line with the findings of Gustavson Gonzalez et al
(2002). However, as we collected only morning spot urines,
the concentrations measured in urine should be interpreted
with caution.
Both BP-3 and OMC are approved as a cosmetic
ingredient in Europe and an over-the-counter drug in the
US by the FDA. The highest approved concentration in
Europe for OMC and BP-3 is 10%. Although the highest
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approved concentration for 4-MBC in Europe in commercial
formula is 4%–6%, the active formulation with 10% (wt/wt)
of all was specifically made for this study (Gagliardi et al,
1987; Lowe, 1998).
4-MBC is only approved in Europe. At the moment the
Danish EPA is advising not to use 4-MBC for children
younger than 12 y because of the insufficient safety profile
for its use in children.
Schlumpf et al (2001) concluded that sunscreens are
potential endocrine disrupters and should be investigated
more closely, in particular penetration through human skin.
They also suggested that the benefits of extensive
sunscreen use may have to be reconsidered from a medical
and ecological perspective.
We observed no biologically significant effects on
hormone levels indicating that the amount of sunscreen
compounds absorbed were not capable of disturbing the
homeostasis of endogenous reproductive hormones in
adults. Minor but statistically significant differences in
hormone levels between the control week and the treatment
week was observed for testosterone, estradiol, and inhibin
B at some time points. These differences, however, did not
seem to be related to the exposure to sunscreen com-
pounds and at least some of these statistically significant
differences between the 2 wk may be chance findings due
to mass significance. Normal biological variations in
hormone levels may have contributed to some of the
differences. This is supported by the fact that for inhibin B in
men and testosterone in women significant differences were
found between the 0-h samples of the 2 wk, although both
samples were drawn before the first application of the
active formulation. Earlier reports substantiate that humans
use less sunscreens than intended by the regulators, under
natural conditions (Deutshes Institut fu¨r Normung, 1985;
Bech-Thomsen and Wulf, 1992–1993; Stender et al,
1996a, b; Wulf et al, 1997). This indicates that in real life
humans are exposed to lower concentrations. Thus, with a
whole-body dermal application of 2 mg cream per cm2 of
Figure 1
Mean serum concentrations of
hormones for males during the
week of treatment with control
cream (  ) and during the week of
treatment with cream containing
sunscreens (  ). All values are
means  SD. Significant differ-
ences in hormone levels at the
same time points between the
2 wk are indicated by po0.01,
po0.05. Differences are com-
pared by a paired t test.
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the three sunscreens in the concentration of 10% (wt/wt)
each we intended to reach maximum exposure.
We applied all three sunscreen compounds simulta-
neously and might expect an additive or possibly even a
synergistic effect. The above findings may indicate that
either adult humans have a high threshold for regulation of
reproductive hormone levels (which is in accordance with
the fact that treatments of postmenopausal women with
high levels of very potent estrogens only have moderate
effects on the gonadotropin levels (Lind et al, 1979; Castelo-
Branco et al, 1993) or the tested sunscreen compounds
have a very low potency for hormone disruption.
The study was designed as single-blinded because we
did not know the baseline hormone level of each subject,
and secondly, if there was a sunscreen effect due to
treatment we did not know how long it would last. Thus, the
control week provided us with the baseline hormone levels
for our subjects.
In conclusion, this study showed that with an whole-
body dermal application of 2 mg cream per cm2 with BP-3,
4-MBC, and OMC used as sunscreens in the concentration
of 10% (wt/wt) each, we were able to detect all three
compounds in their parent forms both in plasma and urine,
showing that there is a substantial skin penetration,
systemic uptake, and urinary excretion of all three com-
pounds in humans. We cannot, however, rule out that data
from this study may not reflect how a single or dual
combination of these three sunscreens may penetrate
human skin. The systemic concentrations achieved of the
‘‘estrogenic’’ sunscreen compounds tested in this short-
term study did not seem to interfere with the hypothalamic–
pituitary–gonadal axis as the endogenous levels of repro-
ductive hormones were unaffected. Prepubertal children,
however, are considered to be more sensitive to low levels
of hormone action due to their low levels of endogenous
reproductive hormones. Young children have less devel-
Figure 2
Mean serum concentrations of
hormones for females during
the week of treatment with
control cream (  ) and during
the week of treatment with
cream containing sunscreens
(  ). All values are means
 SD. Significant differences
in hormone levels at the same
time points between the 2 wk
are indicated by po0.01.
Differences are compared by
a paired t test.
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oped elimination of drugs and larger surface area per body
weight than adults leading to a possible higher uptake and
bio-accumulation. Thus, our results cannot exclude that a
sunscreen treatment similar to the treatment given in this
study might have adverse effects in children.
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